FDA orders eye warnings on GLP-1 drugs

Wednesday, 11 November 2026

Illustrative photo: White and red labeled bottles.

Photo by freestocks on Unsplash

Illustrative photo: White and red labeled bottles.

Lesson plan for about 60 minutes of class time

Interactive lesson: about 15–20 minutes

Warm-up

  1. Have you ever read a medicine label carefully? Why or why not?
  2. What side effects would make you stop a treatment?
  3. How much do you know about eye health and vision loss?

Vocabulary

regulator
an official authority that makes and enforces rules for safety or quality
manufacturer
a company that makes a product, especially on a large scale
label
the printed information on a product's packaging
blindness
the loss of sight, partly or completely
optic
relating to the eye or to vision
disorder
a medical problem that affects how a body part works
risk
the chance that something bad may happen
side effect
an unwanted extra effect that a medicine has on your body

Reading

0:00 / --:--

The US Food and Drug Administration (FDA), the national regulator, has told manufacturers of GLP-1 weight-loss drugs to add a warning about a rare eye disorder linked to sudden blindness. The new label will cover GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound, and will mention non-arteritic anterior ischaemic optic neuropathy (NAION), which happens when blood flow to the optic nerve is blocked. The condition can cause painless loss of vision in one eye, and it may be permanent.

The American Academy of Ophthalmology said any added risk appears small, and it has not been proved these medicines cause NAION. Novo Nordisk, which makes Wegovy, also said current data do not show a cause-and-effect link, but it will keep monitoring safety. A safety arm of the European Medicines Agency has said up to 1 in 10,000 people taking semaglutide may be affected. A US study of 17,000 patients found those on semaglutide were four times more likely to be diagnosed with NAION.

GLP-1 drugs already warn about pancreatitis and gallbladder disease. Common side effects of semaglutide include nausea, vomiting and stomach pain.

Original source

Adapted with AI assistance from the original article. Checked by automated tests before publishing; mistakes found later are corrected. Spotted one? Tell us.

Comprehension

  1. Who ordered the new eye-warning labels on GLP-1 drugs?
  2. Which products will the new label cover?
  3. What is NAION and what can it cause?
  4. What do the American Academy of Ophthalmology and Novo Nordisk say about causation?
  5. What two figures are given about how often NAION may occur?

Grammar focus

Wish / if only

Wish / If only express regrets or desired changes. Forms: wish/if only + past simple (now), wish + past perfect (past regret), wish + would + base verb (change in someone/something). (Examples constructed.)

  • Patients wish they had spoken to a doctor before stopping.
  • If only the warning were clearer on the label.

Practise this grammar: Wish and if only (B2)

More practice on wish and if only: try the grammar bot →

Grammar exercise

Complete the gaps with wish/if only forms: past, past perfect, or would.

  1. Patients wish they (read) ___ the leaflet yesterday.
  2. I wish I already (know) ___ my eye test results.
  3. If only the nausea (go) ___ away soon.
  4. She wishes she (book) ___ an eye test last year.
  5. If only researchers (find) ___ a clear cause now.

Discussion

  1. Should strong side-effect warnings change how people use these drugs?
  2. How much certainty should regulators need before adding a warning?
  3. What advice would you give a friend worried about vision risks?
  4. Are medicine labels clear enough in your country? How could they improve?

For teachers

Timing

  • warm-up · 8–10 minutes
  • vocabulary · 10 minutes
  • reading and comprehension · 12–15 minutes
  • grammar · 8–10 minutes
  • discussion · 12–15 minutes

Teacher's notes

  • Pre-teach or check: GLP-1 (as a type of drug), label, regulator, optic nerve, vision loss, side effect.
  • Run the reading in two passes: gist (who, what, which drugs), then detail (NAION mechanism, figures, positions of the academy and Novo Nordisk). The topic involves serious illness and potential blindness, so start discussion in pairs and allow students to speak about the news rather than personal medical histories.
  • Differentiation: Stronger students summarise each stakeholder’s view (FDA, academy, manufacturer); others match claims to sources using lines drawn on the page.

Answers

Show answers

Comprehension

  1. The US Food and Drug Administration (FDA).
  2. GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound.
  3. Blocked blood flow to the optic nerve; painless vision loss that may be permanent.
  4. Both say it has not been shown that the drugs cause NAION; the academy adds that any added risk seems small.
  5. Up to 1 in 10,000 on semaglutide; a study found people were four times more likely.

Grammar exercise

  1. Patients wish they (read) ___ the leaflet yesterday. had read
  2. I wish I already (know) ___ my eye test results. knew
  3. If only the nausea (go) ___ away soon. would go
  4. She wishes she (book) ___ an eye test last year. had booked
  5. If only researchers (find) ___ a clear cause now. found find / would find

The printable PDF has the same notes and answers, laid out for class.

Start Interactive Lesson

Vocabulary, reading, and exercises with instant feedback

Spotted a mistake in this lesson? Tell us.